EICHORCondition: Solid Tumor · Breast Cancer · Head and Neck Cancer · Sponsor: Oscotec Inc.
This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety and tolerability as monotherapy and in combination with standard-of-care treatments in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Sungsil Lee · 82316287627 · p1401@oscotec.com
Always discuss trial participation with your own doctor first.
| National Cancer Center | Goyang-si, South Korea | Recruiting |
| Seoul National University Bundang Hospital (SNUBH) | Seongnam-si, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Not Yet Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07358806